HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
23 hedge funds and large institutions have $16.4M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 5 closing their positions.
0% more capital invested
Capital invested by funds: $16.4M → $16.4M (+$8K)
4% less funds holding
Funds holding: 24 → 23 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPA
Cowen Prime Advisors
New York
|
+$764K |
| 2 |
SC
Samjo Capital
New York
|
+$751K |
| 3 |
Millennium Management
New York
|
+$93.7K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$19.9K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
-$841K |
| 2 |
Morgan Stanley
New York
|
-$164K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$98.1K |
| 4 |
PP
PDT Partners
New York
|
-$90K |
| 5 |
Squarepoint
New York
|
-$71K |
HTGM Hedge Fund Activity: Q3 2021 in Review
23 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q3 2021, worth a combined $16.4M — up 0.05% from $16.4M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of HTGM and 4 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 4 added.
The largest buyer was Cowen Prime Advisors, adding an estimated $764K. The largest seller was Blue Water Life Science Advisors, exiting entirely with an estimated $841K sold.
- 23 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q3 2021, down from 24 in Q2 2021.
- Funds reported $16.4M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q3 2021, up 0.05% quarter-over-quarter.
- 4 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q3 2021 and 5 closed out, a net change of -1 holder.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q3 2021 was Cowen Prime Advisors, an estimated $764K added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q3 2021 was Blue Water Life Science Advisors, an estimated $841K sold.
Based on aggregated 13F filings for Q3 2021.